Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PepGen, a biotechnology company developing transformative oligonucleotide therapies for individuals living with neuromuscular and neurologic diseases, today announced that it has expanded its leadership team with two key appointments.

Drug development expert Niels Svenstrup, PhD, will join the team as Senior Vice President of Chemistry, Manufacturing.

Dr Svenstrup brings more than 20 years of experience in pharmaceutical research & development to PepGen, where he will oversee the R&D process of the company’s EDO platform. His work has resulted in the invention of numerous drug candidates, of which several are currently in clinical development. Prior to joining PepGen, he served in a variety of life science leadership roles, most recently as Senior Vice President of Development at Cydan, Inc., where he managed chemistry, manufacturing and controls (CMC) operations and strategy and led efforts to identify and de-risk therapeutic candidates for rare diseases.


Experienced financial leader David Pelissier, CPA, will serve as Vice President of Finance. 

Mr Pelissier will leverage his extensive experience leading the financial operations of life science companies in his new role at PepGen. Most recently, he served as Vice President, Controller of AVROBIO, Inc., a company developing gene therapies for lysosomal disorders, subsequent to his role as Senior Director, Controller at Ra Pharmaceuticals, Inc. where he led a myriad of financial activities including executing the acquisition of the company by UCB.

Click here to read the full article


About PepGen

PepGen is advancing a pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), while simultaneously building a team of dedicated industry leaders. While the company’s scientific founders are based in Oxford and Cambridge, UK, PepGen is establishing its U.S. presence in Boston’s biotech hub where Dr Svenstrup and Mr Pelissier will be based.